Screener
CytomX Therapeutics CTMX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
FAQ
- What is CytomX Therapeutics's retained earnings?
- CytomX Therapeutics (CTMX) reported retained earnings of -$750.86M in Q2 2026.
- How has CytomX Therapeutics's retained earnings changed year-over-year?
- CytomX Therapeutics's retained earnings decreased by 12.4% year-over-year, from -$668.21M to -$750.86M.
- What is the long-term trend for CytomX Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), CytomX Therapeutics's retained earnings has grown at a 7.0% compound annual growth rate (CAGR), from -$507.69M to -$711.95M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about CytomX Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude